{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T15:19:53Z","timestamp":1795274393315,"version":"4.10.3"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018096","name":"GOG Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ygyno.2025.03.001","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T17:02:41Z","timestamp":1744304561000},"page":"145-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II\/GOG-3044)"],"prefix":"10.1016","volume":"194","author":[{"given":"Thomas J.","family":"Herzog","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Finkelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndsay","family":"Willmott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Moroney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Buscema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Campbell-Simms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Zweizig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Yu","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutie","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2025.03.001_bb0005","author":"World Cancer Research Fund"},{"key":"10.1016\/j.ygyno.2025.03.001_bb0010","author":"World Health Organization: International Agency for Research on Cancer, Global Cancer Observatory"},{"key":"10.1016\/j.ygyno.2025.03.001_bb0015","series-title":"Cancer Facts & Figures 2024","author":"American Cancer Society","year":"2024"},{"key":"10.1016\/j.ygyno.2025.03.001_bb0020","series-title":"All rights reserved. Accessed November 11, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org","author":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Ovarian Cancer V3.2024\u00a9. National Comprehensive Cancer Network, Inc","year":"2024"},{"issue":"1","key":"10.1016\/j.ygyno.2025.03.001_bb0025","first-page":"15","article-title":"Ovarian cancer screening and early detection in the general population","volume":"4","author":"Rauh-Hain","year":"2011","journal-title":"Rev. Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.03.001_bb0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","article-title":"Epidemiology of ovarian cancer: a review","volume":"14","author":"Reid","year":"2017","journal-title":"Cancer Biol. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2025.03.001_bb0035","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ygyno.2016.03.005","article-title":"Moving beyond the platinum sensitive\/resistant paradigm for patients with recurrent ovarian cancer","volume":"141","author":"Alvarez","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2025.03.001_bb0040","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.03.001_bb0045","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"NEJM"},{"issue":"15","key":"10.1016\/j.ygyno.2025.03.001_bb0050","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1200\/jco.2014.32.15_suppl.5503","article-title":"MITO-11: a randomized multicenter phase II trial testing the addition of pazopanib to weekly paclitaxel in platinum-resistant or refractory advanced ovarian cancer (AOC)","volume":"32","author":"Pignata","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.03.001_bb0055","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/annonc\/mdr149","article-title":"Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from groupe d\u2019Investigateurs nationaux pour i\u2019etude des cancers ovariens (GINECO)","volume":"23","author":"Lortholary","year":"2012","journal-title":"Ann. Oncol."},{"issue":"50","key":"10.1016\/j.ygyno.2025.03.001_bb0060","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1038\/sj.onc.1209085","article-title":"Perturbations of the AKT signaling pathway in human cancer","volume":"24","author":"Altomare","year":"2005","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.ygyno.2025.03.001_bb0065","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signaling in cancer: opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2025.03.001_bb0070","series-title":"InTech","article-title":"Ovarian cancer: A clinical and translational update","author":"Diaz-Padilla","year":"2013"},{"key":"10.1016\/j.ygyno.2025.03.001_bb0075","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1593\/neo.111032","article-title":"DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance","volume":"13","author":"Stronach","year":"2011","journal-title":"Neoplasia"},{"issue":"36","key":"10.1016\/j.ygyno.2025.03.001_bb0080","doi-asserted-by":"crossref","first-page":"33490","DOI":"10.1074\/jbc.M204042200","article-title":"Inhibition of phosphorylation of BAD and Raf-1 by AKT sensitizes human ovarian cancer cells to paclitaxel","volume":"277","author":"Mabuchi","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ygyno.2025.03.001_bb0085","first-page":"573","article-title":"Targeting the PI3K\/AKT\/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer","volume":"4","author":"Rinne","year":"2021","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.ygyno.2025.03.001_bb0090","first-page":"1517","article-title":"Clinical development of AKT inhibitors and associated predictive biomarkers to guide patient treatment in cancer medicine","volume":"14","author":"Coleman","year":"2021","journal-title":"Pharmacogenomics Pers. Med."},{"key":"10.1016\/j.ygyno.2025.03.001_bb0095","series-title":"AACR 2024 presentation of laekna | afuresertib demonstrated promising treatment benefit in combination therapy for drug-resistant TNBC patients","author":"Laekna Therapeutics","year":"2024"},{"issue":"5","key":"10.1016\/j.ygyno.2025.03.001_bb0100","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-18-2277","article-title":"Phase IB dose-escalation and expansion study of AKT inhibitor afuresertib with carboplatin and paclitaxel in recurrent platinum-resistant ovarian cancer","volume":"25","author":"Blagden","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2025.03.001_bb0105","series-title":"Afuresertib Investigator\u2019s Brochure","year":"2019"},{"issue":"6","key":"10.1016\/j.ygyno.2025.03.001_bb0110","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1007\/s10637-018-0591-z","article-title":"A phase 1, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors","volume":"36","author":"Aghajanian","year":"2019","journal-title":"Investig. New Drugs"},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2025.03.001_bb0115","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.3604","article-title":"Results of a phase 1b trial evaluating the safety and clinical activity of sapanisertib (TAK 228) in combination with serabelisib (TAK 117) and paclitaxel in patients with advanced ovarian, endometrial, or breast cancer","volume":"38","author":"Williams","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.03.001_bb0120","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"23","key":"10.1016\/j.ygyno.2025.03.001_bb0125","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1158\/1078-0432.CCR-11-1388","article-title":"Preclinical testing of PI3K\/AKT\/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma","volume":"17","author":"Wu","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ygyno.2025.03.001_bb0130","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5732\/cjc.014.10289","article-title":"The PI3K\/Akt\/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges","volume":"34","author":"Cheaib","year":"2015","journal-title":"Chin. J. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2025.03.001_bb0135","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1200\/JCO.22.02915","article-title":"Ofranergene obadenovec (Ofra-Vec, VB-111) with weekly paclitaxel for platinum-resistant ovarian cancer: randomized controlled phase III trial (OVAL study\/GOG 3018)","volume":"42","author":"Arend","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.03.001_bb0140","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ygyno.2022.01.015","article-title":"Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer","volume":"164","author":"Colombo","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2025.03.001_bb0145","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/jamaoncol.2022.7966","article-title":"Efficacy and safety of weekly paclitaxel plus vistusertib vs paclitaxel alone in patients with platinum-resistant ovarian high-grade serous carcinoma","volume":"9","author":"Banerjee","year":"2023","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.03.001_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190854","article-title":"Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy","volume":"13","author":"Sathe","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2025.03.001_bb0155","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/17425255.2019.1663169","article-title":"Molecular basis for class side effects associated with PI3K\/AKT\/mTOR pathway inhibitors","author":"Zhang","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"9","key":"10.1016\/j.ygyno.2025.03.001_bb0160","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s00228-024-03713-6","article-title":"Treatment-related adverse events in patients with advanced breast cancer receiving adjuvant AKT inhibitors: a meta-analysis of randomized controlled trials","volume":"80","author":"de Moraes","year":"2024","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.03.001_bb0165","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41523-021-00251-7","article-title":"Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer","volume":"7","author":"Smyth","year":"2021","journal-title":"NPJ Breast Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825000708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825000708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:43:12Z","timestamp":1762231392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825000708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":33,"alternative-id":["S0090825825000708"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.03.001","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II\/GOG-3044)","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}